{
  "id": 9026025,
  "title": "Heartflow CMO Campbell Rogers sells $987k in stock",
  "url": "https://urgent.news/2026/09/21/heartflow-cmo-campbell-rogers-sells-987k-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-21T22:46:04.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/heartflow-cmo-campbell-rogers-sells-987k-in-stock-93CH-4909732"
  },
  "original_language": "en",
  "account": "Campbell Rogers, the Chief Medical Officer at Heartflow Inc., sold 19,682 shares of the company's stock on September 18, 2026. The shares were sold at $50.15 each, amounting to $987,052. This sale was performed according to a pre-arranged Rule 10b5-1 trading plan Rogers established on June 16, 2026. At the time of the sale, Heartflow's stock was trading close to its 52-week high of $52.22, following a 93% increase over the past six months.\n\nIn addition to selling shares, Rogers bought back 13,179 shares via option exercises on the same day, valued at $104,587. These shares were purchased at prices between $2.22 and $8.33 per share, and this transaction was also under the Rule 10b5-1 plan. Following the transactions, Rogers holds 79,956 shares of Heartflow directly, as well as indirectly through multiple trusts: 22,615 shares through the Campbell Rogers 2019 Irrevocable Trust, 46,159 shares through the CR Asset Protection Trust of 2023, 26,012 shares through his Spouse's Trust, and 50,754 shares through The Campbell Rogers Revocable Trust.\n\nAnalysts suggest that Heartflow Inc. (HTFL) may be overvalued at its current price. For those interested in a more detailed analysis, the firm provides Pro Research Reports and exclusive metrics for HTFL and over 1,400 other US stocks. Recently, HeartFlow Inc. reported robust financial results for Q2 2026. Despite a narrower-than-expected loss with adjusted earnings of -$0.07 per share, the company beat expectations with revenue rising 48% year-over-year to $64.1 million. This growth was fueled by increased demand for its coronary artery disease diagnostics, surpassing Stifel's forecast of $56.7 million and the consensus estimate of $56.6 million. In response, Stifel raised its price target for HeartFlow shares to $45 from $40, maintaining a Buy rating. The firm's assessment praised HeartFlow's strong performance in its plaque and FFRCT businesses as a major factor in this outperformance.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}